"Gene Therapy: The Time is Now", titles Joshua Schimmer of Piper Jaffray his study by Lazard Capital Markets. Literally every week is there an announcement, publication or patent filing regarding viral vectors and their use in Gene Function Research, Target Validation, Gene Therapy or Vaccines. Difficult to keep track.
It is of critical importance to stay on top of the many developments; SIRION Biotech is leading the field of viral vector supplies in Europe for almost 10 years. Please find here Application Releases, SIRION's regular Newsletter on latest technical findings (please sign up for it below), News of Interest, Investor News and Media Coverage.
SIRION Biotech is being advised by LaVoie HealthScience.